Oral, mouse: LD50 = 23 mg/kg; Oral, rat: LD50 = 30 mg/kg. Symptoms of overdose include nausea and vomiting.
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus.L12867,A193419 It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix.A193419 Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies.A193419
Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC)L12867 - as well as adjunctly to ab externo glaucoma surgeries.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Mitomycin. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Mitomycin. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mitomycin. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mitomycin. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mitomycin. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mitomycin. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Mitomycin. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mitomycin. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mitomycin. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mitomycin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Mitomycin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitomycin. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mitomycin. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Mitomycin. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mitomycin. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mitomycin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Mitomycin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitomycin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Mitomycin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitomycin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitomycin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitomycin. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Mitomycin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitomycin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitomycin. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mitomycin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitomycin. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mitomycin. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Mitomycin. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Mitomycin. |
| Cladribine | Mitomycin may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Mitomycin. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Mitomycin. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Mitomycin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Mitomycin. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mitomycin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Mitomycin is combined with Bexarotene. |
| Floxuridine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Floxuridine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Indomethacin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Tioguanine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Mitomycin is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Mitomycin is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of adverse effects can be increased when Mitomycin is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Trifluridine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Gemcitabine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Mitomycin is combined with Betamethasone. |
| Teniposide | The risk or severity of adverse effects can be increased when Mitomycin is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Mitomycin is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Mitomycin is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Mitomycin is combined with Cyclophosphamide. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Mitomycin is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Pentostatin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Mitomycin is combined with Methotrexate. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Carbamazepine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Mitomycin is combined with Linezolid. |
| Imatinib | The risk or severity of adverse effects can be increased when Mitomycin is combined with Imatinib. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Mitomycin is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Mitomycin is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Mitomycin is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mitomycin is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Daunorubicin. |
| Tretinoin | The risk or severity of cardiotoxicity can be increased when Mitomycin is combined with Tretinoin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Mitomycin is combined with Irinotecan. |
| Methimazole | The risk or severity of adverse effects can be increased when Mitomycin is combined with Methimazole. |
| Etoposide | The risk or severity of adverse effects can be increased when Mitomycin is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Mitomycin is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Mitomycin is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Mitomycin is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Mitomycin is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Mitomycin is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Mitomycin is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mitomycin is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Mitomycin is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Mitomycin is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Mitomycin is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fludarabine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Flucytosine. |
| Capecitabine | The risk or severity of adverse effects can be increased when Mitomycin is combined with Capecitabine. |